总时间（秒）：30.50
问答时间（秒）：29.72

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly establishes that LRRK2 kinase activity is altered in PD and that modulating this activity may be therapeutic.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity. Furthermore, using an in vitro kinase activity assay, we demonstrate that at ATP concentrations close to cellular levels (1 mM) I2020T is approximately 10-fold more resistant to ATP-competitive kinase inhibitors than wild-type whereas G2019S is 1.6-fold more sensitive.",
          "judgment": "Yes",
          "reasoning": "The in vitro kinase activity assay directly assesses the function of the kinase domain, which is central to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity.",
          "judgment": "No",
          "reasoning": "While the method mentions enzymatic assays, the paper does not explicitly state that ‘normal/negative/wild type’ controls were used in conjunction with the assay. ",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
         {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are standard in the field for investigating kinase function and are widely accepted.",
          "next_step_or_outcome": "Proceed to Step 4"
        }
      ],
      "odds_path_information": "No OddsPath calculated.",
      "functional_evidence_strength": "Max PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly establishes that LRRK2 kinase activity is altered in PD and that modulating this activity may be therapeutic.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity. Furthermore, using an in vitro kinase activity assay, we demonstrate that at ATP concentrations close to cellular levels (1 mM) I2020T is approximately 10-fold more resistant to ATP-competitive kinase inhibitors than wild-type whereas G2019S is 1.6-fold more sensitive.",
          "judgment": "Yes",
          "reasoning": "The in vitro kinase activity assay directly assesses the function of the kinase domain, which is central to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity.",
          "judgment": "No",
          "reasoning": "While the method mentions enzymatic assays, the paper does not explicitly state that ‘normal/negative/wild type’ controls were used in conjunction with the assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
         {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP afﬁnity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are standard in the field for investigating kinase function and are widely accepted.",
          "next_step_or_outcome": "Proceed to Step 4"
        }
      ],
      "odds_path_information": "No OddsPath calculated.",
      "functional_evidence_strength": "Max PS3_supporting"
    }
  ]
}
```